Welcome to HTI Consultancy,
where we help you to gain insights on the position of your health innovation in comparison to the current health lanscape.
I am Katharina, a health economics expert for health innovations.
In health economics we utilize mathematical models to estimate the health benefit of a health technology and the associated costs compared to what’s currently available to patients. Based on health economic principles, the strengths and weaknesses of the technology can be identified.
“Does your technology perform better than your competitors?
That’s a big plus!
What about the costs? Are they higher, and if so, how much better does your health technology have to perform to balance out those extra costs?"
If you do not know the answer yet, let’s get together, and find out!
HTI can help you with questions on…
Pricing strategies
What is the potential monetary value of my technology given its expected health benefits?
What is the potential maximum benefit I could achieve with my health technology in its field of application?
Where in the care pathway should I position my health technology?
Reimbursement
I was asked to provide a budget impact analysis/ cost-effectiveness analysis for my health technology. What do I need to do? How can I provide this?
What health economics data do I need to collect in my study for reimbursement?
What do I need to do to get my technology reimbursed?
Investor readiness
We conducted a study and want to know whether the new technology could be reimbursed.
Does my health innovation have a potential monetary benefit? And if so, what is the magnitude?
Do you have a different question regarding your health technology? Reach out to find out what is needed to answer your questions.
In a clinical trial, a client tested the impact of their digital health innovation on the health condition of cancer survivors. In addition to clinical effectiveness, data on healthcare resource consumption, such as specialist & GP visits, medicine use and care provided, was collected. Estimating the difference in costs between the innovation and the current care on population level, informed the client on the next steps of reimbursement and their investment strategy.
A client was interested in the monetary value of their health innovation for ulcerative colitis compared to the current treatments. Since they were early in the development, the clinical pathway of three different patient populations could be modelled. Based on the early cost-effectiveness analysis, the client could be informed on the population(s) with the highest monetary value to guide their next steps in the product development.
Examples from previous clients
A client was early in their technology development, so the potential health benefit needed to be based mainly on expert input. The technology had not been tested in trial, yet, but the client needed to know which patient population would benefit most. And if the type of treatment administration would result in higher costs and/or lower health benefit. We built an early cost-effectiveness model to help the client understand how much better their innovation had to perform compared to the current technologies, and informed them on the maximum reimbursement price possible given expected performance.
Abraham et al. (2024) Benefits of a digital health technology for elderly nursing home residents. A de-novo cost-effectiveness model of a Digital Health Technology to aid in the assessment of toileting and containment care needs. PLoS ONE.
van Lieshout et al. (2024) A cost-utility analysis of cochlear implants for single sided deafness in adults and children in the Netherlands. PLoS ONE.
Abraham et al. (2024) A blueprint for HTA capacity building: Lessons learned from Malta. International Journal of Technology Assessment in Health Care.
Abraham & Franken (2023). A SWOT analysis of the complex interdependencies of the Maltese reimbursement processes. Health Policy OPEN, 4, 1-8. Article 100095.
A client, familiar with the reimbursement landscape, requested a cost-effectiveness analysis for their medical device for the Dutch setting. They weren’t sure yet which of the two patient population would benefit most from their medical device, so both were evaluated. Following the Dutch health economic guidelines, a cost-effectiveness model was developed. The resulting cost and health benefit trade-off for each of the two patient populations guided the client in their strategic choice for which population to apply for reimbursement.
Publications in Health Economics
Our services
Health economic literature review
Reviewing, analysing and reporting of health economic literature relevant to the planning of trials, initial evaluation of the potential health and cost benefit or for selecting a target population.
Support
When short on manpower for building/reviewing economic models, reviewing pharmaco-economic dossiers or for supporting data analysis (max 6 months).
Cost-effectiveness analysis
Advising on & building the appropriate health economic models needed for pricing strategies, reimbursement, and investor readiness based on health economics principles.
Contact HTI
Let’s get in contact to find out the needs to make your innovative health technology a success!
You can fill in the form and I will contact you for a first online call or in-person meeting to find out together what the next steps could be.
Alternatively you can send a message directly to:
